Editorial: Ethics in Antiretroviral Therapy

Editorial Commentary: Age-Old Questions: When to Start Antiretroviral Therapy and in Whom?

Two seemingly unrelated themes have emerged in human immunodeficiency virus (HIV) research over recent years. One relates to the increasing evidence that early introduction of antiretroviral therapy (ART) in infected individuals is preferable to delayed therapy, and the second to the interactions between HIV and aging in our population. The article by Edwards et al in this issue of Clinical Inf...

Publication ethics: clinical chemistry editorial standards.

In the last decade there has been increasing adverse publicity regarding the ethics of researchers, and in some cases journals, for not presenting research data and conclusions in an honest and transparent manner. As editors, we acknowledge our responsibility in making efforts toward reversing this trend. Therefore, on the first anniversary of Clinical Chemistry’s new editorial team, we want to...

Editorial independence and ethics of research publication.

Metabolic Abnormalities in HIV-Positive Patients Receiving Highly Active Antiretroviral Therapy

Background and Objective: Dyslipidemia has become a common problem in human immunodeficiency virus (HIV) disease, especially in patients on combination antiretroviral therapy. In this study we aimed to determine the prevalence of dyslipidemia and metabolic abnormalities in 2 groups of HIV infected patients receiving highly activ...

Advances in antiretroviral therapy.

The 14th Conference on Retroviruses and Opportunistic Infections provided a forum for presentation of state-of-the-art research on antiretroviral therapy. This year's conference marked the first public presentation of phase III trials of the lead compounds in 2 new drug classes: maraviroc (a CCR5 inhibitor) and raltegravir (an HIV-1 integrase inhibitor). These agents are likely to be approved b...